Breaking News Instant updates and real-time market news.

BHC

Bausch Health

$22.57

-0.3 (-1.31%)

, CLSD

Clearside Biomedical

$0.80

-0.0206 (-2.51%)

07:04
10/23/19
10/23
07:04
10/23/19
07:04

Bausch Health acquires exclusive license for Xipere from Clearside Biomedical

Bausch Health (BHC) and Bausch + Lomb, its global eye health business, and Clearside Biomedical (CLSD) announced that an affiliate of Bausch Health has acquired an exclusive license for the commercialization and development of Xipere in the United States and Canada. Xipere is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for suprachoroidal administration via Clearside's proprietary SCS Microinjector that is being investigated as a targeted treatment of macular edema associated with uveitis. Clearside expects to resubmit its new drug application, or NDA, for Xipere to the FDA for review in Q1 and believes the FDA will review the NDA within six months of receipt of the resubmission.

BHC

Bausch Health

$22.57

-0.3 (-1.31%)

CLSD

Clearside Biomedical

$0.80

-0.0206 (-2.51%)

  • 04

    Nov

  • 04

    Nov

BHC Bausch Health
$22.57

-0.3 (-1.31%)

09/11/19
GUGG
09/11/19
INITIATION
Target $30
GUGG
Buy
Bausch Health initiated with a Buy at Guggenheim
Guggenheim analyst Dana Flanders started Bausch Health with a Buy rating and $30 price target.
09/11/19
GUGG
09/11/19
INITIATION
GUGG
Buy
Bausch Health initiated with a Buy at Guggenheim
Guggenheim analyst Dana Flanders initiated Bausch Health with a Buy rating and a $30 price target, citing the company's strong execution and the durability of its businessses. Flanders believes Bausch will lower its $27B in debt over the next few years, which "should translate to a double-digit compounded equity return for shareholders."
09/17/19
WELS
09/17/19
NO CHANGE
WELS
Underperform
Wells says two of Bausch's 'Significant Seven' not on UnitedHealth benefit list
Wells Fargo analyst David Maris noted that United Healthcare (UNH) released its Pharmacy Benefit Coverage update, which shows that as of January 2020 it is excluding Bausch Health's (BHC) Bryhali, which he said is one of the company's "Significant Seven" focus products. Another of the Significant Seven, Siliq, will no longer be covered under UnitedHealth's pharmacy benefit plans, said Maris. Two other Significant Seven members - Vyzulta and Relistor - are listed as required step therapy and needing a prior authorization, respectively, Maris added. The analyst, who thinks Bausch Health's pipeline and recently approved products are "unimpressive," keeps an Underperform rating on the stock. Reference Link
10/03/19
PIPR
10/03/19
NO CHANGE
Target $29
PIPR
Overweight
Bausch unlikely to face generic Xifaxan before 2028, says Piper Jaffray
Piper Jaffray analyst David Amsellem says he would not be worried that a generic Xifaxan entrant will emerge prior to the January 2028 launch date outlined in Bausch Health Companies' (BHC) settlement with Teva (TEVA) on its generic filing. The analyst highlights the "relatively complex nature" of Xifaxan and Bausch's "fairly deep intellectual property estate." As such, he continues to believe that visibility into a "durable" EBITDA for Bausch Health is high, with a longer-term annual growth "reaching at least the high single digits." He reiterates an Overweight rating on the shares with a $29 price target.
CLSD Clearside Biomedical
$0.80

-0.0206 (-2.51%)

08/13/19
LDLW
08/13/19
DOWNGRADE
LDLW
Hold
Clearside Biomedical downgraded to Hold from Buy at Laidlaw
08/13/19
LDLW
08/13/19
DOWNGRADE
Target $2
LDLW
Hold
Laidlaw downgrades Clearside Biomedical to Hold after Xipere partnering
As previously reported, Laidlaw analyst Francois Brisebois downgraded Clearside Biomedical to Hold from Buy as he believes the company's decision to out-license their main product, Xipere, adds uncertainty for the foreseeable future in terms of topline growth. He lowered his price target on Clearside shares to $2 from $5, stating that he values CLS-TA for U.S. uveitis at $1.50 per share and the company's cash and technology at 50c per share.
08/22/19
JMPS
08/22/19
NO CHANGE
JMPS
Clearside Biomedical price target lowered to $3 from $4 at JMP Securities
JMP Securities analyst Donald Ellis reiterated an Outperform rating on Clearside Biomedical, but it lowering his price target on shares to $3 from $4 after the FDA requested additional stability data for Xipere, which will delay a final FDA approval and require an NDA re-submission in Q1 of 2020. Ellis added that he now sees Xipere approval in Q3 of 2020.
10/14/19
ROTH
10/14/19
NO CHANGE
ROTH
Ophthalmic therapies 'could go from 0 to 100 real quick,' says Roth Capital
Commenting on the Ophthalmology space, Roth Capital analyst Zegbeh Jallah highlights her conviction for stronger valuations, driven by the increasing number of companies with innovative pipelines, and pending changes at both the FDA and CMS. The analyst suspects that these changes could lead to more wins in the space, which could drive valuations. Further, she cautions investors to keep "their eyes peeled on developments in the space." Jallah sees this as possible relevant for KalVista (KALV), Regenxbio (RGNX), Kala Pharmaceuticals (KALA), Kodiak Sciences (KOD), Regeneron (REGN), Aerie Pharmaceuticals (AERI), Applied Genetic (AGTC), Aldeyra (ALDX), Adverum Biotechnologies (ADVM), Clearside Biomedical (CLSD), Ocugen (OCGN), and many others.

TODAY'S FREE FLY STORIES

AXNX

Axonics

$25.49

0.53 (2.12%)

06:09
11/14/19
11/14
06:09
11/14/19
06:09
Hot Stocks
Axonics announces FDA approval of Axonics r-SNM System »

Axonics announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 21

    Nov

EPAM

Epam Systems

$200.74

0.85 (0.43%)

06:09
11/14/19
11/14
06:09
11/14/19
06:09
Initiation
Epam Systems initiated  »

Epam Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

FENG

Phoenix New Media

$3.04

0.04 (1.33%)

06:07
11/14/19
11/14
06:07
11/14/19
06:07
Hot Stocks
Phoenix New Media declares 17.14c per share special cash dividend »

The company also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATHX

Athersys

$1.37

0.04 (3.01%)

06:07
11/14/19
11/14
06:07
11/14/19
06:07
Hot Stocks
Athersys: Healios receives orphan designation for ARDS clinical program »

Athersys announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$48.44

0.06 (0.12%)

06:06
11/14/19
11/14
06:06
11/14/19
06:06
Recommendations
Cisco analyst commentary  »

Piper stays on sidelines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

GRUB

GrubHub

$36.63

-0.7 (-1.88%)

06:05
11/14/19
11/14
06:05
11/14/19
06:05
Periodicals
GrubHub to create 'task force' after NYC Council threatens action, NYP says »

GrubHub will create a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTT

Wireless Telecom Group Inc

$1.50

0.04 (2.74%)

06:05
11/14/19
11/14
06:05
11/14/19
06:05
Hot Stocks
Wireless Telecom Group Inc to Acquire Holzworth Instrumentation »

Wireless Telecom Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

FVRR

Fiverr

$22.55

0.99 (4.59%)

06:04
11/14/19
11/14
06:04
11/14/19
06:04
Upgrade
Fiverr rating change  »

Fiverr upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

ROLL

RBC Bearings

$165.06

-1.19 (-0.72%)

06:04
11/14/19
11/14
06:04
11/14/19
06:04
Downgrade
RBC Bearings rating change  »

RBC Bearings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWK

Stanley Black & Decker

$155.38

-2.295 (-1.46%)

06:04
11/14/19
11/14
06:04
11/14/19
06:04
Upgrade
Stanley Black & Decker rating change  »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

NRZ

New Residential

$16.06

-0.07 (-0.43%)

06:03
11/14/19
11/14
06:03
11/14/19
06:03
Downgrade
New Residential rating change  »

New Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBEV

New Age Beverages

$2.50

0.04 (1.63%)

06:02
11/14/19
11/14
06:02
11/14/19
06:02
Earnings
New Age Beverages reports Q3 EPS (14c), consensus (4c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

SFTBF

SoftBank

$0.00

(0.00%)

, SFTBY

SoftBank

$0.00

(0.00%)

06:02
11/14/19
11/14
06:02
11/14/19
06:02
Periodicals
SoftBank's Yahoo Japan in talks to merge with Naver's Line, Nikkei reports »

SoftBank's Yahoo…

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$48.44

0.06 (0.12%)

06:01
11/14/19
11/14
06:01
11/14/19
06:01
Recommendations
Cisco analyst commentary  »

Citi keeps Buy on Cisco…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

XRX

Xerox

$37.60

0.14 (0.37%)

, HPQ

HP Inc.

$19.54

-0.005 (-0.03%)

06:00
11/14/19
11/14
06:00
11/14/19
06:00
Periodicals
Carl Icahn pushes for Xerox, HP Inc union, WSJ reports »

Carl Icahn, who owns a…

XRX

Xerox

$37.60

0.14 (0.37%)

HPQ

HP Inc.

$19.54

-0.005 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 09

    Dec

MYO

Myomo

$0.54

-0.1126 (-17.26%)

05:58
11/14/19
11/14
05:58
11/14/19
05:58
Downgrade
Myomo rating change  »

Roth Capital downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLGT

Fulgent Genetics

$13.62

0.11 (0.81%)

05:57
11/14/19
11/14
05:57
11/14/19
05:57
Syndicate
Fulgent Genetics 2.325M share Spot Secondary priced at $11.25 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

ECOR

electroCore

$1.88

0.06 (3.30%)

05:56
11/14/19
11/14
05:56
11/14/19
05:56
Downgrade
electroCore rating change  »

electroCore downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECOR

electroCore

05:56
11/14/19
11/14
05:56
11/14/19
05:56
Downgrade
electroCore rating change  »

electroCore downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

05:55
11/14/19
11/14
05:55
11/14/19
05:55
Conference/Events
SunTrust hosted company meetings at conference »

SunTrust hosted Meetings…

NICE

Nice

$159.16

0.87 (0.55%)

05:54
11/14/19
11/14
05:54
11/14/19
05:54
Earnings
Nice raises FY19 EPS view to $5.15-$5.35 from $5.13-$5.33, consensus $5.26 »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 19

    Nov

  • 26

    Nov

EMR

Emerson

$73.10

-0.47 (-0.64%)

05:52
11/14/19
11/14
05:52
11/14/19
05:52
Downgrade
Emerson rating change  »

HSBC downgrades Emerson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 21

    Nov

NICE

Nice

$159.16

0.87 (0.55%)

05:51
11/14/19
11/14
05:51
11/14/19
05:51
Earnings
Nice reports Q3 EPS $1.30, consensus $1.28 »

Reports Q3 revenue $386M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 19

    Nov

  • 26

    Nov

MIME

Mimecast

$43.42

0.28 (0.65%)

05:50
11/14/19
11/14
05:50
11/14/19
05:50
Hot Stocks
Mimecast acquires DMARC Analyzer »

Mimecast announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

PRGS

Progress Software

$41.49

-0.36 (-0.86%)

05:48
11/14/19
11/14
05:48
11/14/19
05:48
Hot Stocks
Progress Software appoints Katie Kulikoski as Chief People Officer »

Progress announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.